Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer
Science Translational Medicine · 15.11.2023 · 15 (722)
DOI: 10.1126/scitranslmed.adf6732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 15.11.2023. Verfasst von Yasutaka Yamada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms, Neuroendocrine Tumors, Antineoplastic Agents. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Aberrant DNA methylation has been implicated as a key driver of prostate cancer lineage plasticity and histologic transformation to neuroendocrine prostate cancer (NEPC). DNA methyltransferases (DNMTs) are highly expressed, and global DNA methylation is dysregulated in NEPC. We identified that deletion of DNMT genes decreases expression of neuroendocrine lineage markers and substantially reduced NEPC tumor development and metastasis in vivo. Decitabine, a pan-DNMT inhibitor, attenuated tumor growth in NEPC patient–derived xenograft models, as well as retinoblastoma gene ( RB1 )–deficient castration-resistant prostate adenocarcinoma (CRPC) models compared with RB1 -proficient CRPC. We further found that DNMT inhibition increased expression of B7 homolog 3 (B7-H3), an emerging druggable target, via demethylation of B7-H3. We tested DS-7300a (i-DXd), an antibody-drug conjugate targeting B7-H3, alone and in combination with decitabine in models of advanced prostate cancer. There was potent single-agent antitumor activity of DS-7300a in both CRPC and NEPC bearing high expression of B7-H3. In B7-H3–low models, combination therapy of decitabine plus DS-7300a resulted in enhanced response. DNMT inhibition may therefore be a promising therapeutic target for NEPC and RB1-deficient CRPC and may sensitize B7-H3–low prostate cancer to DS-7300a through increasing target expression. NEPC and RB1-deficient CRPC represent prostate cancer subgroups with poor prognosis, and the development of biomarker-driven therapeutic strategies for these populations may ultimately help improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Harvard Medical School, Boston, MA 02215, USA.
ORCID-Profile: Yasutaka Yamada, Varadha Balaji Venkadakrishnan, Kei Mizuno, Martin Bakht, Sheng-Yu Ku, Maria Mica Garcia, Himisha Beltran
Förderung
- NCI NIH HHS
Zitieren
APA
Yamada, Y., Venkadakrishnan, V. B., Mizuno, K., Bakht, M., Ku, S. Y., Garcia, M. M., & Beltran, H. (2023). Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Science Translational Medicine, 15(722). https://doi.org/10.1126/scitranslmed.adf6732
Vancouver
Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM, et al. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Science Translational Medicine. 2023;15(722). doi:10.1126/scitranslmed.adf6732
BibTeX
@article{Yamada2023,
author = {Yamada, Yasutaka and Venkadakrishnan, Varadha Balaji and Mizuno, Kei and Bakht, Martin and Ku, Sheng-Yu and Garcia, Maria Mica and Beltran, Himisha},
title = {Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {722},
doi = {10.1126/scitranslmed.adf6732}
}
EUVIMED